PMDA
- Application: Sarclisa
- Local brand name: Sarclisa
- Status: approved
🇯🇵 isatuximab SAR650984 IV in Japan
isatuximab SAR650984 IV (isatuximab SAR650984 IV) regulatory status in Japan.
Marketing authorisation
isatuximab SAR650984 IV in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is isatuximab SAR650984 IV approved in Japan?
Yes. PMDA has authorised it.
Who is the marketing authorisation holder for isatuximab SAR650984 IV in Japan?
Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.